Staphylococcus Lugdunensis Prosthetic Joint Infection

Overview

Staphylococcus lugdunensis is a coagulase-negative staphylococcus belonging to the human commensal cutaneous flora, and has been little studied in the field of prosthetic joint infections. However, it shares many virulence traits with Staphylococcus aureus, including many adhesins and its ability to form biofilm, and the few series of cases reports a significant failure rate.

Full Title of Study: “Staphylococcus Lugdunensis Prosthetic Joint Infection: a Retrospective Cohort Study”

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Retrospective
  • Study Primary Completion Date: April 1, 2021

Interventions

  • Other: Prothestic joint infection due to Staphylococcus lugdunensis
    • description of prosthetic joint infection with Staphylococcus lugdunensis

Arms, Groups and Cohorts

  • Prothestic joint infection due to Staphylococcus lugdunensis
    • Patients having had a prosthetic joint infection with Staphylococcus lugdunensis

Clinical Trial Outcome Measures

Primary Measures

  • Rate of PJI infection with Staphylococcus lugdunensis
    • Time Frame: between 2010 and 2020
    • proportion of patients having PJI infection with Staphylococcus lugdunensis, alone or with other bacteria
  • Description of PJI infection with Staphylococcus lugdunensis : type
    • Time Frame: Outcome is measured at the end of follow-up (usually between 12 and 24 months after antibiotic therapy disruption
    • type of PJI : knee or hip prosthesis
  • Description of PJI infection with Staphylococcus lugdunensis : evolution
    • Time Frame: Outcome is measured at the end of follow-up (usually between 12 and 24 months after antibiotic therapy disruption
    • evolution of PJI :evolution between prosthesis placement and the onset of symptoms, gateway to infection
  • Description of patients with PJI infection due to Staphylococcus lugdunensis
    • Time Frame: Outcome is measured at the end of follow-up (usually between 12 and 24 months after antibiotic therapy disruption
    • type of patients: age, CMI
  • Description of patients with PJI infection due to Staphylococcus lugdunensis : follow up
    • Time Frame: Outcome is measured at the end of follow-up (usually between 12 and 24 months after antibiotic therapy disruption
    • duration of the follow up of patients
  • Description of patients with PJI infection due to Staphylococcus lugdunensis : medical treatment
    • Time Frame: Outcome is measured at the end of follow-up (usually between 12 and 24 months after antibiotic therapy disruption
    • description and duration of antibiotics
  • Description of patients with PJI infection due to Staphylococcus lugdunensis : surgical treatment
    • Time Frame: Outcome is measured at the end of follow-up (usually between 12 and 24 months after antibiotic therapy disruption
    • description of surgery performed : DAIR, one-step exchange, two-step exchange
  • rate of treatment failure
    • Time Frame: Outcome is measured at the end of follow-up (usually between 12 and 24 months after antibiotic therapy disruption
    • Treatment failure is defined by local clinical and/or microbiological relapse; and/or need for additional surgery; death of septic origin

Participating in This Clinical Trial

Inclusion Criteria

  • infection of joint prosthesis (whatever its type) with Staphylococcus lugdunensis defined by the positivity of at least 2 gold-standard samples (joint puncture, intraoperative samples) with S. lugdunensis; OR – a single positive gold-standard sample or positive blood cultures AND formal clinical, radiological, biological and / or pathological arguments in favor of an infection of joint prosthesis AND absence of other pathogenic agent Exclusion Criteria:

  • none

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Hospices Civils de Lyon
  • Provider of Information About this Clinical Study
    • Sponsor

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.